Open Access
| Issue |
Med Sci (Paris)
Volume 36, Number 12, Décembre 2020
Vieillissement et mort : de la cellule à l’individu
|
|
|---|---|---|
| Page(s) | 1216 - 1217 | |
| Section | Le Magazine | |
| DOI | https://doi.org/10.1051/medsci/2020236 | |
| Published online | 09 December 2020 | |
- Fritz JM, Lenardo MJ. Development of immune checkpoint therapy for cancer. J Exp Med 2019 ; 216 : 1244–1254. [CrossRef] [PubMed] [Google Scholar]
- Bommareddy PK, Shettigar M, Kaufman HL. Integrating oncolytic viruses in combination cancer immunotherapy. Nat Rev Immunol 2018 ; 18 : 498–513. [CrossRef] [PubMed] [Google Scholar]
- Guillerme J-B, Boisgerault N, Roulois D, et al. Measles virus vaccine-infected tumor cells induce tumor antigen cross-presentation by human plasmacytoid dendritic cells. Clin Cancer Res 2013 ; 19 : 1147–1158. [CrossRef] [PubMed] [Google Scholar]
- Aznar MA, Molina C, Teijeira A, et al. Repurposing the yellow fever vaccine for intratumoral immunotherapy. EMBO Mol Med 2020; 12 : e10375. [CrossRef] [PubMed] [Google Scholar]
- Ribas A, Dummer R, Puzanov I, et al. Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy. Cell 2017 ; 170 : 1109–19 e10. [CrossRef] [PubMed] [Google Scholar]
- Zamarin D, Holmgaard RB, Subudhi SK, et al. Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy. Sci Transl Med 2014; 6 : 226ra32. [CrossRef] [PubMed] [Google Scholar]
- Barrett ADT. Yellow fever live attenuated vaccine: A very successful live attenuated vaccine but still we have problems controlling the disease. Vaccine 2017 ; 35 : 5951–5955. [CrossRef] [PubMed] [Google Scholar]
- Achard C, Boisgerault N, Delaunay T, et al. Sensitivity of human pleural mesothelioma to oncolytic measles virus depends on defects of the type I interferon response. Oncotarget 2015 ; 6 : 44892–44904. [CrossRef] [PubMed] [Google Scholar]
- Galanis E, Atherton PJ, Maurer MJ, et al. Oncolytic measles virus expressing the sodium iodide symporter to treat drug-resistant ovarian cancer. Cancer Res 2015 ; 75 : 22–30. [CrossRef] [Google Scholar]
Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.
Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.
Initial download of the metrics may take a while.